-DOCSTART- -X- O
The -X- _ O
success -X- _ O
of -X- _ O
lentiviral -X- _ B-Intervention
vectors -X- _ I-Intervention
in -X- _ O
curing -X- _ O
fatal -X- _ O
genetic -X- _ O
and -X- _ O
acquired -X- _ O
diseases -X- _ O
has -X- _ O
opened -X- _ O
a -X- _ O
new -X- _ O
era -X- _ O
in -X- _ O
human -X- _ O
gene -X- _ O
therapy. -X- _ O
However -X- _ O
, -X- _ O
variability -X- _ O
in -X- _ O
the -X- _ O
efficacy -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
this -X- _ O
therapeutic -X- _ O
approach -X- _ O
has -X- _ O
been -X- _ O
reported -X- _ O
in -X- _ O
human -X- _ B-Patient
patients. -X- _ I-Patient
Consequently -X- _ O
, -X- _ O
lentiviral-vector-based -X- _ B-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
is -X- _ O
limited -X- _ O
to -X- _ O
incurable -X- _ O
human -X- _ O
diseases -X- _ O
, -X- _ O
with -X- _ O
little -X- _ O
understanding -X- _ O
of -X- _ O
the -X- _ O
underlying -X- _ O
causes -X- _ O
of -X- _ O
adverse -X- _ O
effects -X- _ O
and -X- _ O
poor -X- _ O
efficacy. -X- _ O
To -X- _ O
assess -X- _ O
the -X- _ O
role -X- _ O
that -X- _ O
host -X- _ O
genetic -X- _ O
variation -X- _ O
has -X- _ O
on -X- _ O
efficacy -X- _ O
of -X- _ O
gene -X- _ O
therapy -X- _ O
, -X- _ O
we -X- _ O
characterized -X- _ O
lentiviral-vector -X- _ B-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
within -X- _ O
a -X- _ O
set -X- _ O
of -X- _ O
12 -X- _ B-Patient
collaborative -X- _ I-Patient
cross -X- _ I-Patient
mouse -X- _ I-Patient
strains. -X- _ I-Patient
Lentiviral -X- _ B-Intervention
vectors -X- _ I-Intervention
carrying -X- _ I-Intervention
the -X- _ I-Intervention
firefly -X- _ I-Intervention
luciferase -X- _ I-Intervention
cDNA -X- _ I-Intervention
under -X- _ I-Intervention
the -X- _ I-Intervention
control -X- _ I-Intervention
of -X- _ I-Intervention
a -X- _ I-Intervention
liver-specific -X- _ I-Intervention
promoter -X- _ I-Intervention
were -X- _ O
administered -X- _ O
to -X- _ O
female -X- _ B-Patient
mice -X- _ I-Patient
, -X- _ O
with -X- _ O
total-body -X- _ O
and -X- _ O
hepatic -X- _ O
luciferase -X- _ O
expression -X- _ O
periodically -X- _ O
monitored -X- _ O
through -X- _ O
41 -X- _ O
weeks -X- _ O
post-vector -X- _ O
administration. -X- _ O
Vector -X- _ O
copy -X- _ O
number -X- _ O
per -X- _ O
diploid -X- _ O
genome -X- _ O
in -X- _ O
mouse -X- _ O
liver -X- _ O
and -X- _ O
spleen -X- _ O
was -X- _ O
determined -X- _ O
at -X- _ O
the -X- _ O
end -X- _ O
of -X- _ O
this -X- _ O
study. -X- _ O
We -X- _ O
identified -X- _ O
major -X- _ O
strain-specific -X- _ O
contributions -X- _ O
to -X- _ O
overall -X- _ O
success -X- _ O
of -X- _ O
transduction -X- _ O
, -X- _ O
vector -X- _ B-Outcome
biodistribution -X- _ I-Outcome
, -X- _ I-Outcome
maximum -X- _ I-Outcome
luciferase -X- _ I-Outcome
expression -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
kinetics -X- _ I-Outcome
of -X- _ I-Outcome
luciferase -X- _ I-Outcome
expression -X- _ I-Outcome
throughout -X- _ I-Outcome
the -X- _ I-Outcome
study. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
highlight -X- _ O
the -X- _ O
importance -X- _ O
of -X- _ O
genetic -X- _ O
variation -X- _ O
on -X- _ O
gene- -X- _ O
therapeutic -X- _ O
efficacy -X- _ O
; -X- _ O
provide -X- _ O
new -X- _ O
models -X- _ O
with -X- _ O
which -X- _ O
to -X- _ O
more -X- _ O
rigorously -X- _ O
assess -X- _ O
gene -X- _ O
therapy -X- _ O
approaches -X- _ O
; -X- _ O
and -X- _ O
suggest -X- _ O
that -X- _ O
redesigning -X- _ O
preclinical -X- _ O
studies -X- _ O
of -X- _ O
gene-therapy -X- _ O
methodologies -X- _ O
might -X- _ O
be -X- _ O
appropriate -X- _ O
. -X- _ O

